Simpson Thacher is representing Warburg Pincus in connection with the launch of Vertice Pharma, LLC with an equity investment of up to $300 million. Warburg Pincus has partnered with pharmaceutical industry veterans, Don DeGolyer and Andrew Saik to launch the new company. Vertice Pharma also announced a definitive merger agreement to acquire VistaPharm. The terms of the transaction were not disclosed.~~Vertice Pharma is a specialty pharmaceuticals company that develops, manufactures, markets, and distributes high-quality and affordable pharmaceutical products through its operating companies.~~VistaPharm, founded in 1998, is a Florida-based healthcare company that specializes in delivering generic pharmaceutical and OTC products for the hospital market, retail pharmacy and specialized clinical setting.~~The Simpson Thacher team included Robert Langdon, Austen Heim and Colin Lloyd (M&A – U.S.); Mike Wolfson, Neil Evans and Chris Vallance (M&A – U.K.); Jason Vollbracht and Judy Yan (Tax); David Rubinsky, Jeannine McSweeney and Eric Wolf (Executive Compensation and Employee Benefits); Jennifer Hobbs, Brian Gluck and Homin Lee (Debt); Timothy Mulvihill (Environmental); Peter Thomas and Michael Naughton (Antitrust); and Genevieve Dorment (Intellectual Property).